Sagimet Biosciences Q4 net loss narrows as R&D expenses fall

Sagimet Biosciences

11/03/2026 11:39

Overview

U.S. biopharma firm's Q4 net loss narrowed yr/yr

Q4 research and development expense declined from prior year

Company completed Phase 1 trial for denifanstat/resmetirom combo and saw positive Phase 3 acne data from partner

Outlook

Sagimet plans Phase 2 denifanstat/resmetirom trial in F4 MASH patients in 2H 2026

Company expects to start Phase 2 TVB-3567 acne trial in 2026, pending Phase 1 completion

Result Drivers

R&D SPENDING - Q4 research and development expense declined by 52.6% yr/yr to $6.7 mln, contributing to a narrower net loss

Company press release: ID:nGNX7NkT6k

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.29
Q4 Net Income
-$9.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sagimet Biosciences Inc is $27.00, about 388.2% above its March 10 closing price of $5.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)